No Phase I remedies in Merck, Schering-Plough review raises prospect of unconditional EC clearance
Merck’s purchase of rival pharmaceuticals company Schering-Plough appears to be on course for unconditional Phase I approval by the European Commission after the company passed up the chance to offer remedies...To view the full article, register now.
Already a subscriber? Click here to view full article